(Press-News.org) An assay designed to measure normal and abnormal forms of the huntingtin protein – the mutated form of which causes Huntington's disease (HD) – was successful in detecting levels of the mutant protein in a large multicenter study of individuals at risk for the devastating neurological disorder. The report from a team of Massachusetts General Hospital (MGH) investigators – which will appear in the Sept. 24 issue of Neurology and has been released online – also found changes in levels of the mutated protein that might predict when symptoms will appear.
"Our validation of this biomarker for measuring the huntingtin protein in the blood of individuals with HD supports its usefulness in monitoring treatments designed to affect the mutant protein," says Steven Hersch, MD, PhD, of the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND), senior author of the report. "Our results also suggest that this assay might sense biological stresses in the body that occur as the disease becomes symptomatic in individuals who have inherited the HD mutation."
Inheriting a single mutated copy of the huntingtin gene causes deposition of the abnormal form of the protein within the brain. The toxic effects of the mutant protein eventually produce symptoms such as uncontrolled movements, erratic emotions and dementia. Symptoms of HD usually first appear in the middle years and worsen over the 10- to 30-year course of the disorder, leading to death from a variety of complications. A genetic test for the HD mutation has been available since the gene was discovered at MGH more that 20 years ago, but since there currently is no way to delay or slow the progression of symptoms, many individuals at risk for the disorder choose not to learn their gene status. Several potential therapies in development are designed to reduce levels of mutant huntingtin, but studies are currently hampered by difficulty in assessing the drugs' effectiveness, especially in early-phase trials.
Several years ago a collaboration led by Anne Young, MD, PhD, former chief of Neurology at MGH and a co-author of the Neurology paper, developed the assay used in the current study. The assay uses what is called HTRF technology and a set of three antibodies against the huntingtin protein – including one specific for the mutation site – to measure the relative levels of the mutant and total huntingtin proteins. Previous studies have confirmed the ability of HTRF assay to measure normal and mutant huntingtin in animal models of the disease and in blood cells and brain tissue samples from HD patients.
The current study was designed to validate those results in a large multicenter study of presymptomatic individuals known to be at risk for the disease as well as in patients with early symptoms. The researchers analyzed white blood cells collected from participants in PHAROS (Prospective Huntington At-Risk Observational Study). This National Institutes of Health investigation – led by Young and Ira Shoulson, MD, of Georgetown University, also a coauthor of the current study – was conducted from 1999 to 2009 and enrolled 1,000 individuals who had a parent or sibling with the disorder but had not learned their gene status. Blood samples from 342 participants, collected at 35 centers around the U.S., were suitable for analysis with the HTRF assay.
The researchers determined that 228 participants had 36 or fewer CAG repeats – repetitions of a particular nucleotide sequence within the huntingtin gene – indicating the normal form of the gene. The other 114, including 26 who had developed symptoms during the course of PHAROS, had 37 or more repeats, reflecting the HD mutation. Among participants with expanded CAG repeats, the HTRF assay signal for mutant huntingtin was significantly stronger than among those with normal CAG repeats. In participants with CAG expansion, analyzing HTRF results in relation to either the estimated time to symptom onset or the time when symptoms appeared suggested that assay results might change with the appearance of symptoms.
"These findings raise the possibility that this assay could help predict symptom onset or progression; however, a long-term study that follows a group of participants as their symptoms appear and progress is needed to confirm this," says Hersch. "Right now we can use the assay in clinical trials to measure whether experimental treatments affect levels of mutant huntingtin in blood, an indicator that they may be working as hoped. Eventually we should be able to ask whether reduced blood levels, as measured by HTRF, correspond to an effective treatment for HD."
Study lead author Miriam Moscovitch-Lopatin, PhD, also of MGH-MIND, adds, "The extensive and consistent quality controls at the clinical sites, as well as those applied by our team in processing blood samples and performing the HTRF assay, were essential for the success of this study and will be vital for the future use of the assay." She is an instructor in Neurology, and Hersch is a professor of Neurology at Harvard Medical School.
INFORMATION:
Additional co-authors of the Neurology paper are Rachel Goodman, James Ritch, Diana Rosas, MD, MSc, and Samantha Matson, MassGeneral Institute for Neurodegenerative Disease; Shirley Eberly, MS, and David Oakes, PhD, University of Rochester; and Wayne Matson, DSc, Veteran's Administration Hospital, Bedford, Mass. The study was supported by National Institute of Neurological Disorders and Stroke grants UO1NS071789 and PO1NS058793.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.
END
(SACRAMENTO, Calif.) — Glucose monitoring systems with an autocorrect feature that can detect red blood cells (hematocrit), vitamin C and other common interferents in burn patients' blood are better for monitoring care, a pilot study conducted by UC Davis researchers at the School of Medicine and College of Engineering has found. The study was published in the Journal of Burn Care Research.
Burn patients are at risk for high blood glucose levels, or hyperglycemia, due to the body's stress response. Intensive insulin therapy, which is commonly used to keep glucose under ...
Alcohol intoxication reduces communication between two areas of the brain that work together to properly interpret and respond to social signals, according to researchers at the University of Illinois at Chicago College of Medicine.
Their results were published in the September issue of Psychopharmacology.
Previous research has shown that alcohol suppresses activity in the amygdala, the area of the brain responsible for perceiving social cues such as facial expressions.
"Because emotional processing involves both the amygdala and areas of the brain located in the prefrontal ...
A recent study by UC Santa Barbara scientists analyzed whole-body fish samples taken from oil-and-gas production platforms and natural sites for heavy metal pollutants. The results showed all but four elements were relatively consistent at both types of location. The findings were published in the Bulletin of Marine Science.
The research, led by fish expert Milton S. Love, a research biologist with UCSB's Marine Science Institute, entailed collecting a total of 196 fish –– 18 kelp bass (Paralabrax clathratus), 80 kelp rockfish (Sebastes atrovirens), and 98 Pacific sanddab ...
Researchers have identified a protein that they believe may help predict breast cancer prognosis, potentially relieving thousands of women at low risk from having to undergo painful, oft-debilitating therapies, while insuring the most successful treatments for those at high risk. The research was published ahead of print in the journal Molecular and Cellular Biology.
Using bioinformatics techniques, the authors showed that the levels of expression of some 1,200 genes that are directly controlled by the enzyme, EZH2, correlates with the aggressiveness of breast cancer ...
In the search for clean, green sustainable energy sources to meet human needs for generations to come, perhaps no technology matches the ultimate potential of artificial photosynthesis. Bionic leaves that could produce energy-dense fuels from nothing more than sunlight, water and atmosphere-warming carbon dioxide, with no byproducts other than oxygen, represent an ideal alternative to fossil fuels but also pose numerous scientific challenges. A major step toward meeting at least one of these challenges has been achieved by researchers with the U.S. Department of Energy ...
SEATTLE – A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production – both of which impact immune function – increase the risk of developing prostate cancer.
The findings, by Stanford and colleagues from the University of Washington Genome Sciences Department and the National Human Genome Research Institute, are online ahead of the print issue of Cancer Epidemiology, Biomarkers & Prevention.
A ...
This news release is available in French. Despite all the research done on Alzheimer's, there is still no early diagnostic tool for the disease. By looking at the brain wave components of individuals with the disease, Professor Tiago H. Falk of INRS's Centre Énergie Matériaux Télécommunications has identified a promising avenue of research that may not only help diagnose the disease, but also assess its severity. This non-invasive, objective method is the subject of an article in the journal PLOS ONE.
Patients with Alzheimer's disease currently undergo neuropsychological ...
University of Alberta researchers have found that abundant materials in the Earth's crust can be used to make inexpensive and easily manufactured nanoparticle-based solar cells.
The U of A discovery, several years in the making, is an important step forward in making solar power more accessible to parts of the world that are off the traditional electricity grid or face high power costs, such as the Canadian North, said researcher Jillian Buriak, a chemistry professor and senior research officer of the National Institute for Nanotechnology, based on the U of A campus.
Buriak ...
PHILADELPHIA— A new drug target to treat depression and other mood disorders may lie in a group of GABA neurons (gamma-aminobutyric acid –the neurotransmitters which inhibit other cells) shown to contribute to symptoms like social withdrawal and increased anxiety, Penn Medicine researchers report in a new study in the Journal of Neuroscience.
Experts know that people suffering from depression and other mood disorders often react to rejection or bullying by withdrawing themselves socially more than the average person who takes it in strides, yet the biological processes ...
Research findings provide direct evidence that people with chronic diseases are more likely to be food insecure - that is suffering from inadequate, insecure access to food as a result of financial constraints. Previous research has shown that food insecurity rates are highest among low-income households, in households reliant on social assistance, reporting Aboriginal status, renting rather than owning their dwelling, and lone-parent female-led (see recent annual report from PROOF). Even taken together though, these factors provide only a partial explanation for the vulnerability ...
